title: Integrins and adhesion molecules as targets to treat inflammatory bowel disease.
abstract: Inflammatory bowel diseases (IBD) present a typically relapsing-remitting behavior and are characterized by a disabling and progressive course. Anti-tumor necrosis factor (TNF)-α agents have drastically changed the therapeutic management of IBD. However, a significant proportion of patients does not have a primary response, some patients lose response overtime and/or experience side effects. Recently, anti-adhesion molecules were investigated and showed efficacy with a good safety profile. Vedolizumab was recently approved for both Crohn's disease (CD) and ulcerative colitis (UC) and several other molecules are under evaluation in this field. Anti-adhesion molecules could represent a potential therapeutic option for future therapy in IBD. In this review we report the efficacy and safety of major anti-adhesion drugs in active IBD patients.
authors.affiliation: IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy.
authors.forename: Ivana
authors.initials: I
authors.lastname: Bravatà
authors.affiliation: IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy.
authors.forename: Mariangela
authors.initials: M
authors.lastname: Allocca
authors.affiliation: IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy.
authors.forename: Gionata
authors.initials: G
authors.lastname: Fiorino
authors.affiliation: IBD Center, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy; Humanitas University, Department of Biomedical Sciences, Rozzano, Milan, Italy. Electronic address: sdanese@hotmail.com.
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000378:metabolism*; D016023:Integrins / Q000037:antagonists & inhibitors*; D008954:Models, Biological; D058990:Molecular Targeted Therapy / Q000379:methods*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D016023:Integrins